Sugi Predict

Sugi Predict / Compounds / Benzophenone

Benzophenone

Benzophenone

SCHEMBL3857530

N[C@@H](Cc1ccccc1)C(=O)O.O=C(c1ccccc1)c1ccccc1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 7/20 0.81
▸ ALPI P09923 1/20 0.81
▸ PKM P14618 1/20 0.81
▸ PTGS1 P23219 1/20 0.81
▸ XIAP P98170 1/20 0.81
▸ SLC1A3 P43003 2/20 0.59
▸ SLC1A2 P43004 2/20 0.59
▸ SLC1A1 P43005 2/20 0.59
▸ SLC15A1 P46059 1/20 0.54
▸ TPH1 P17752 2/20 0.54
▸ NOS3 P29474 1/20 0.54
▸ NOS1 P29475 1/20 0.54
▸ NOS2 P35228 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ MDM2 Q00987 1/20 0.52
▸ LTA4H P09960 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzophenone SCHEMBL3857526 1.00 SLC7A5 (0.81) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL44096 0.95 SLC7A5 (0.72) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL44097 0.95 SLC7A5 (0.72) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL288025 0.95 SLC7A5 (0.72) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL6494649 0.93 SLC7A5 (0.71) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL6494644 0.93 SLC7A5 (0.71) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL7109453 0.92 SLC7A5 (0.96) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL23159186 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL837632 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL8118 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5221736-A Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques BIONEBRASKA, INC. (US) 1993-06-22 — — US claimed
EP-0449980-A4 SEQUENTIAL PEPTIDE AND OLIGONUCLEOTIDE SYNTHESIS USING IMMUNOAFFINITY TECHNIQUES — 1991-11-21 — — EP claimed
EP-0449980-A1 SEQUENTIAL PEPTIDE AND OLIGONUCLEOTIDE SYNTHESIS USING IMMUNOAFFINITY TECHNIQUES BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1991-10-09 — — EP claimed
WO-1990006936-A1 SEQUENTIAL PEPTIDE AND OLIGONUCLEOTIDE SYNTHESIS USING IMMUNOAFFINITY TECHNIQUES BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1990-06-28 — — WO claimed
US-7482425-B2 Compositions for lipid matrix-assisted chemical ligation AMYLIN PHARMACEUTICALS, INC. (US) 2009-01-27 — — US disclosed
EP-1107979-B1 LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES GRYPHON THERAPEUTICS INC (US) 2006-07-05 — — EP disclosed
US-20050089970-A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use AMYLIN PHARMACEUTICALS, INC. 2005-04-28 — — US disclosed
EP-1299415-A4 CHEMOKINE RECEPTOR MODULATORS, PRODUCTION AND USE GRYPHON THERAPEUTICS INC (US) 2005-01-19 — — EP disclosed
US-6844161-B2 Modular protein libraries and methods of preparation GRYPHON THERAPEUTICS, INC. (US) 2005-01-18 — — US disclosed
EP-1307216-A4 POLYMER-MODIFIED BIOACTIVE SYNTHETIC CHEMOKINES, AND METHODS FOR THEIR MANUFACTURE AND USE GRYPHON THERAPEUTICS INC (US) 2005-01-12 — — EP disclosed
US-20040077835-A1 Chemokine receptor modulators, production and use AMYLIN PHARMACEUTICALS, INC. 2004-04-22 — — US disclosed
CN-1460023-A Polymer modified bioactive synthetic chemokines and methods of production and use GRYPHON TREAT CO (US) 2003-12-03 — — CN disclosed
WO-2002004499-A1 CHEMOKINE RECEPTOR MODULATORS, PRODUCTION AND USE GRYPHON THERAPEUTICS, INC. (US) 2002-01-17 — — WO disclosed
EP-1159289-A1 CHEMICAL SYNTHESIS AND USE OF SOLUBLE MEMBRANE PROTEIN RECEPTOR DOMAINS Gryphon Sciences (US) 2001-12-05 — — EP disclosed
CN-1325405-A Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides GYPHON SCIENCES (US) 2001-12-05 — — CN disclosed
EP-1107979-A2 LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES Gryphon Sciences (US) 2001-06-20 — — EP disclosed
WO-2000053624-A1 CHEMICAL SYNTHESIS AND USE OF SOLUBLE MEMBRANE PROTEIN RECEPTOR DOMAINS GRYPHON SCIENCES (US) 2000-09-14 — — WO disclosed
EP-1009757-A1 MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION Gryphon Sciences (US) 2000-06-21 — — EP disclosed
WO-2000012536-A2 LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES GRYPHON SCIENCES (US) 2000-03-09 — — WO disclosed
WO-1999011655-A1 MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION GRYPHON SCIENCES (US) 1999-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050089970-A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use CCL11, CCL2, ACKR3 SLC7A5 4227/4885ALPI 2415/4885PKM 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.